Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brenda F Baker

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Molecular Therapy. Nucleic Acids|May 1, 2013
A Selective Inhibitor of Human C-reactive Protein Translation Is Efficacious In Vitro and in C-reactive Protein Transgenic Mice and HumansNicholas R Jones, Melissa A Pegues, Mark A McCrory, et al.
The American Journal of Cardiology|May 11, 2010
Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemiaFatima Akdim, Maartje E Visser, Diane L Tribble, et al.
The New England Journal of Medicine|December 4, 2014
Targeting APOC3 in the familial chylomicronemia syndromeDaniel Gaudet, Diane Brisson, Karine Tremblay, et al.
Nucleic Acid Therapeutics|February 2, 2017
The Effects of 2'-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical TrialsStanley T Crooke, Brenda F Baker, Joseph L Witztum, et al.
Lancet (London, England)|July 27, 2015
Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 studySotirios Tsimikas, Nicholas J Viney, Steven G Hughes, et al.
Diabetes Care|June 9, 2016
Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 DiabetesAndres Digenio, Richard L Dunbar, Veronica J Alexander, et al.
Muscle & Nerve|July 13, 2020
mNIS+7 and lower limb function in inotersen treatment of hereditary transthyretin-mediated amyloidosisP James B Dyck, John C Kincaid, Janice F Wiesman, et al.
Diabetes Care|February 16, 2019
Antisense Inhibition of Glucagon Receptor by IONIS-GCGR<sub>Rx</sub> Improves Type 2 Diabetes Without Increase in Hepatic Glycogen Content in Patients With Type 2 Diabetes on Stable Metformin TherapyErin S Morgan, Li-Jung Tai, Nguyen C Pham, et al.
Circulation Research|April 2, 2013
Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humansMark J Graham, Richard G Lee, Thomas A Bell, et al.
Journal of the American College of Cardiology|April 10, 2010
Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapyFatima Akdim, Erik S G Stroes, Eric J G Sijbrands, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Molecular Therapy. Nucleic Acids|May 1, 2013
A Selective Inhibitor of Human C-reactive Protein Translation Is Efficacious In Vitro and in C-reactive Protein Transgenic Mice and HumansNicholas R Jones, Melissa A Pegues, Mark A McCrory, et al.
The American Journal of Cardiology|May 11, 2010
Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemiaFatima Akdim, Maartje E Visser, Diane L Tribble, et al.
The New England Journal of Medicine|December 4, 2014
Targeting APOC3 in the familial chylomicronemia syndromeDaniel Gaudet, Diane Brisson, Karine Tremblay, et al.
Nucleic Acid Therapeutics|February 2, 2017
The Effects of 2'-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical TrialsStanley T Crooke, Brenda F Baker, Joseph L Witztum, et al.
Lancet (London, England)|July 27, 2015
Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 studySotirios Tsimikas, Nicholas J Viney, Steven G Hughes, et al.
Diabetes Care|June 9, 2016
Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 DiabetesAndres Digenio, Richard L Dunbar, Veronica J Alexander, et al.
Muscle & Nerve|July 13, 2020
mNIS+7 and lower limb function in inotersen treatment of hereditary transthyretin-mediated amyloidosisP James B Dyck, John C Kincaid, Janice F Wiesman, et al.
Diabetes Care|February 16, 2019
Antisense Inhibition of Glucagon Receptor by IONIS-GCGR<sub>Rx</sub> Improves Type 2 Diabetes Without Increase in Hepatic Glycogen Content in Patients With Type 2 Diabetes on Stable Metformin TherapyErin S Morgan, Li-Jung Tai, Nguyen C Pham, et al.
Circulation Research|April 2, 2013
Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humansMark J Graham, Richard G Lee, Thomas A Bell, et al.
Journal of the American College of Cardiology|April 10, 2010
Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapyFatima Akdim, Erik S G Stroes, Eric J G Sijbrands, et al.
Pageof 6